- Home
- GORO vs CING Comparison
GORO vs CING Comparison
Compare GORO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- CING
- Stock Information
- Founded
- GORO 1998
- CING 2012
- Country
- GORO United States
- CING United States
- Employees
- GORO N/A
- CING N/A
- Industry
- GORO Precious Metals
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- GORO Basic Materials
- CING Health Care
- Exchange
- GORO Nasdaq
- CING Nasdaq
- Market Cap
- GORO 17.1M
- CING 15.3M
- IPO Year
- GORO N/A
- CING 2021
- Fundamental
- Price
- GORO $0.33
- CING $4.62
- Analyst Decision
- GORO Strong Buy
- CING Strong Buy
- Analyst Count
- GORO 1
- CING 3
- Target Price
- GORO $1.75
- CING $16.00
- AVG Volume (30 Days)
- GORO 3.5M
- CING 222.0K
- Earning Date
- GORO 03-12-2025
- CING 11-07-2024
- Dividend Yield
- GORO N/A
- CING N/A
- EPS Growth
- GORO N/A
- CING N/A
- EPS
- GORO N/A
- CING N/A
- Revenue
- GORO $73,897,000.00
- CING N/A
- Revenue This Year
- GORO N/A
- CING N/A
- Revenue Next Year
- GORO $48.90
- CING N/A
- P/E Ratio
- GORO N/A
- CING N/A
- Revenue Growth
- GORO N/A
- CING N/A
- 52 Week Low
- GORO $0.12
- CING $1.80
- 52 Week High
- GORO $0.71
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- GORO 56.63
- CING 47.61
- Support Level
- GORO $0.34
- CING $4.35
- Resistance Level
- GORO $0.49
- CING $5.09
- Average True Range (ATR)
- GORO 0.06
- CING 0.38
- MACD
- GORO -0.01
- CING -0.06
- Stochastic Oscillator
- GORO 40.10
- CING 32.93
About GORO Gold Resource Corporation
Gold Resource Corp is a gold and silver producer, developer, and explorer with operations in Oaxaca, Mexico, and Nevada, USA. It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.